Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia-Reference-Cited by-同舟云学术

Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia

Published:2022-03-18 Issue:6 Volume:97 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Kennedy Vanessa E.¹^ORCID,Hui Gavin²,Azenkot Tali³,Gaut Daria⁴,Wieduwilt Matthew J.⁵,Oliai Caspian⁴^ORCID,Jonas Brian A.⁶^ORCID,Mittal Varun¹,Logan Aaron C.¹^ORCID,Muffly Lori S.⁷,Mannis Gabriel N.⁸

Affiliation:

1. Division of Hematology/Oncology, Department of Medicine University of California San Francisco California USA

2. Department of Medicine Stanford University Stanford California USA

3. Department of Medicine University of California Davis California USA

4. Division of Hematology/Oncology, Department of Medicine University of California Los Angeles California USA

5. Section of Hematology/Oncology, Department of Medicine University of Oklahoma Oklahoma City Oklahoma USA

6. Division of Hematology/Oncology, Department of Medicine University of California Davis California USA

7. Division of Blood and Marrow Transplantation, Department of Medicine Stanford University Stanford California USA

8. Division of Hematology, Department of Medicine Stanford University Stanford California USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26524

Reference10 articles.

1. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

2. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

3. Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

4. Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia

5. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant?;Leukemia & Lymphoma;2024-07-23

2. Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics;Science Translational Medicine;2024-06-05

3. A Remission by Any Other Means May Smell as Sweet;The Hematologist;2024

4. The approach of HMA plus VEN with or without BMT for all patients with AML;Hematology;2023-12-08

5. Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes;ImmunoTargets and Therapy;2023-11